LTR Pharma Income Statement

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '24 Dec 31, 2024	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Other Revenue	0.05	0.05	-	0.01	-
Revenue	0.5	0.05	-	0.01	-
Gross Profit	0.93	0.05	-	0.01	-
Selling, General & Admin	2.05	1.65	0.59	0.68	0.03
Research & Development	3.51	3.51	0.82	0.35	-
Other Operating Expenses	0.7	0.53	0.03	-	-
Operating Expenses	7.73	6.99	1.44	1.03	0.03
Operating Income	-6.8	-6.94	-1.44	-1.02	-0.03
Interest Expense	-0	-0	-0	-0	-0.01
Interest & Investment Income	0	0	0	0	0
Currency Exchange Gain (Loss)	-0.02	-0.01	-0.02	-0.01	-0
Pretax Income	-6.82	-6.95	-1.45	-1.03	-0.04
Net Income	-6.82	-6.95	-1.45	-1.03	-0.04
Net Income to Common	-6.82	-6.95	-1.45	-1.03	-0.04
Shares Outstanding (Basic)	146	139	260	-	-
Shares Outstanding (Diluted)	146	139	260	-	-
Shares Change (YoY)	-47.24%	-46.36%	-	-	-
EPS (Basic)	-0.05	-0.05	-0.01	-	-
EPS (Diluted)	-0.05	-0.05	-0.01	-	-
Free Cash Flow	-5.29	-5.09	-1.54	-0.57	-0.03
Free Cash Flow Per Share	-0.04	-0.04	-0.01	-	-
Gross Margin	186.35%	100.00%	-	100.00%	-
Operating Margin	-1360.63%	-14162.27%	-	-11195.03%	-
Profit Margin	-1365.16%	-14192.25%	-	-11314.40%	-
Free Cash Flow Margin	-1058.85%	-10396.58%	-	-6258.86%	-
EBIT	-6.8	-6.94	-1.44	-1.02	-0.03
Advertising Expenses	-	-	-	0	0.01

Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.